reports
- Ingird Gafanhão
- Alex Cogut
- Ingird Gafanhão
CALLIDITAS BUY – SEK 190 TP | Here we go, IgAN! Initiating coverage on...
CALLIDITAS initiation of coverage BUY – SEK 190 TP CALLIDITAS BUY – SEK 190 TP | Here we go, IgAN! Initiating coverage on the IgAN leader Calliditas is a late-stage Swedish biotech with a commercial-stage product, nefecon, and a clinical-stage asset, setanaxib. Nefecon is the first and only drug approved for IgA nephropathy (IgAN) – H1 2022 US sales show good momentum (SEK 81.6m) which we expect to improve based on the current unmet need in IgAN. On the clinical catalyst side, we are confide...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.